---
title: Houde CA, Khan A, Jacobus SJ, etÂ al. Treatment outcomes and prognostic factors
  with lenalidomide, bortezomib, and dexamethasone (RVd) alone versus Rvd plus autologous
  stem cell transplantation (ASCT) in African American (AA) patients (Pts) with newly
  diagnosed multiple myeloma (NDMM) in the Determination phase 3 trial [abstract].
  Blood. 2023;142(suppl 1):4762
date: '2024-06-20'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38900470/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240620182039&v=2.18.0.post9+e462414
source: Blood
description: No ...
disable_comments: true
---
No ...